Chronic Beta2-adrenergic Stimulation and Cardiac and Skeletal Muscle Hypertrophy

University of Copenhagen42 enrolled

Overview

Studies in animals have shown that beta2-adrenoceptor activation with selective agonists regulates protein metabolism and muscle growth in skeletal and cardiac muscle tissue. These effects may be mediated by cAMP/PKA dependent activation of several downstream sites that modulate protein synthesis and breakdown. While the role of beta2-adrenoceptor signaling is well-described in animals, it is inadequately explored in humans. The purpose of the study is thus to investigate the effect of chronic beta2-adrenergic stimulation (cAMP/PKA-signaling) on muscle hypertrophy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

TRIPLE

Enrollment

Conditions

Muscle Hypertrophy in Healthy Young Men

Interventions

SalbutamolDRUG

PlaceboDRUG

Resistance trainingOTHER

Eligibility

Sex: MALEMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Physical active * Non-smokers * Non-asthmatics * No chronic diseases * Informed consent Exclusion Criteria: * Smoker * Allergy towards study drug

Outcomes

Primary Outcomes

Skeletal Muscle Hypertrophy (lean body mass in Kilograms)

Lean body mass (kg) will be measured at two different days by Dual X-ray absorbance (DXA)

Time frame: 2 days

Secondary Outcomes

Left Ventricular Hypertrophy (mass in grams)

Left Ventricular Mass (g) will be measured by echocardiography of the heart

Time frame: 1 day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.